Author

P. Pohlmann

h-index 7 View on Semantic Scholar

We have 2 of 37 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Aug 2026

Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial

A phase 2 clinical trial investigating neoadjuvant zanidatamab (HER2-targeting antibody) in patients with early-stage HER2-positive breast cancer found de-escalation to HER2-targeted therapy alone may be feasible.

V. Valero, P. Pohlmann, J. Mouabbi et al. · Nature Communications · 0 citations

Open access Sep 2026

TALAVE in Breast Cancer: BRCA1/2 Mutation-Dependent Immune Remodeling after PARP Inhibition with Limited Checkpoint Engagement

Only limited benefit of PD-1/PD-L1 blockade in augmenting PARPi activity is suggested and the need for alternative strategies to sustain PARPi-induced immunity is highlighted.

F. Lynce, Kenichi Shimada, Claudine Isaacs et al. · bioRxiv · 0 citations